Aprocitentan(Tryvio)is an oral medication and an administered dual endothelin A/endothelin B(ETA/ETB)receptor antagonist.It is approved by the U.S.Food and Drug administration(FDA)on March 19,2024.It is used in combination with other antihypertensive drugs,to lower blood pressure in adult patients who are not adequately controlled on other traditional drugs.Through a comprehensive review of the mechanism of action,pharmacokinetics,clin-ical trials,adverse effects,considerations for specific patient populations,and precautions regarding aprocitentan,this aims to provide clinical physicians with new strategies for the treatment of resistant hypertension(RH).
Antihypertensive agentsEndothelin receptor antagonistsHypertension,treatment-resistantPhar-macological and toxicological phenomena
维普
万方数据
